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Aim: To evaluate the association of NOS1 and NOS3 gene polymorphisms with the risk/severity of neonatal
respiratory distress syndrome (RDS) among preterm infants.
Methods: The patient group was 189 preterm infants diagnosed with RDS. The control group was 227 preterm
neonates who did not develop RDS. NOS genotyping was performed using an improved multiplex ligation
detection reaction (iMLDR) technique based on LDR.
Results: It was found that genotype and allele frequencies of rs2682826 of the NOS1 gene and rs1799983 of the
NOS3 gene were not significantly different between the RDS group and the control group. However, when the
preterm infants were divided into two and three groups based on gestational age and birth weight, a study of the SNP
rs1799983 of the NOS3 gene showed that the GG genotype and G allele frequencies were significantly increased in the
RDS groups, the GT genotype and A allele were less frequent among the RDS groups in 26–32.9 weeks of gestational
age and in a birth weight subgroup of <1.5 Kg.
Conclusion: Our study raises the possibility that a genetic variation of NOS3 could be implicated in the
pathophysiology of RDS in the Chinese Han population, especially in very preterm and very low birth weight infants.
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PolymorphismIntroduction
Nitric oxide (NO) is a modulator of apoptotic and inflam-
matory cascades and endothelial permeability; it is synthe-
sised by nitric oxide synthase (NOS) from L-arginine. In
humans, neuronal NOS (nNOS) encoded by NOS1, indu-
cible NOS (iNOS) encoded by NOS2A, and endothelial
NOS (eNOS) encoded by NOS3 are three isoforms of
NOS that are expressed in airway epithelium [1]. It has
been identified that endogenous NO is vital for the de-
crease in pulmonary vascular resistance and the improve-
ment in ventilation-perfusion matching after birth, which
enables pulmonary hypertension to be reversed. NOS3 de-
ficiency in mice causes abnormalities in lung morphogen-
esis, which results in respiratory distress and death within
the first few hours of life [2]. Furthermore, clinical trials* Correspondence: wangbin6556@126.com; zengqy_zj@163.com
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unless otherwise stated.proved that inhaled nitric oxide had beneficial effects on
respiratory outcomes [3,4].
NOS1 is located on chromosome 12q24.2 and is com-
posed of 29 exons and 28 introns, which encompass
more than 160 kb of genomic DNA [5]. The rs2682826
SNP is located in the 3′-UTR of exon 29 of the NOS1
gene. Given the known function of 3′-UTR in the de-
generative stability and translational efficiency of mRNA,
we cannot exclude the possibility that the rs2682826
SNP can be functionally important [6]. NOS3 is located
on chromosome 7q35-36, it shows a single nucleotide
polymorphism in exon 7, Glu298Asp (G894T, rs1799983),
which results in a substitution of glutamic acid by aspartic
acid at amino acid position 298 [7]. The Glu298Asp poly-
morphism was suggested to be associated with altered
NOS3 enzyme activity, reduced NO production, and
blunted endothelial-dependent vasodilation.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to understand individual variability in their susceptibility
to the pathologies of pulmonary disease, especially RDS,
which is the most frequent form of respiratory failure
in preterm infants. There has been no study that in-
vestigated the role of NOS1 polymorphisms in RDS in
preterm neonates. The association between the NOS3
gene and NRDS has been investigated in recent studies
among Turkish population, but the data remain incon-
sistent [8,9] and the association between them among
Chinese population is still unclear.
The Chinese population has over 1,30 billion people,
in which the Han population is over 1,17 billion. Due to
the variable genetic polymorphisms and distinct geo-
graphic residency and environment, predisposition and
susceptibility to diseases vary. The aim of the present
study is to determine whether the polymorphisms of
NOS1 and NOS3 genes in preterm babies were associ-
ated with RDS in a Chinese Han population.
Materials and methods
Study population
A total of 416 patients were recruited from Zhujiang
Hospital and Guangzhou Woman and Children’s Medical
Center from October 2009 to February 2013 for the study.
The RDS group was composed of 189 neonates from un-
related families. We defined RDS as the need for supple-
mental oxygen, a chest radiograph consistent with RDS
and the need for continuous positive airway pressure or
mechanical ventilation within the first 24 hours of life.
The control group was composed of 227 preterm infants
without RDS. Exclusion criteria were congenital anomal-
ies, severe infection, and inherited metabolic disorders.
Clinical data concerning gestational age, sex, birth weight,
and maternal and neonatal clinical histories were obtained
from the medical records. The gestational age of the in-
fants were determined based on early ultrasound esti-
mates of gestation and date of LMP. Informed consent
was obtained from the parents of the infants, and the
study protocol was approved by the local Ethics Committee
of Southern Medical University.
DNA isolation
Genomic DNA was extracted from 2 ml of EDTA-
anticoagulated peripheral blood samples, using the
QIAamp DNA Kit (Qiagen, Hilden, Germany ) accord-
ing to the manufacturer’s instructions.
SNP genotyping using the iMLDR™ technique
The SNP genotyping work was performed using an im-
proved multiplex ligation detection reaction (iMLDR)
technique, which was newly developed by Genesky
Biotechnologies Inc. (Shanghai, China). This method was
based on LDR. In this study, we applied the iMLDRtechnique on the genotyping of 2 SNP loci in one ligation
reaction, which is the rs2682826 polymorphism of the
NOS1 gene and the rs1799983 polymorphism of the
NOS3 gene. A multiplex of PCR reactions was designed to
amplify the 2 SNP loci. The first PCR reaction in 20 μl
contained 1x PCR buffer (Takara), 3.0 mM Mg2+, 0.3 mM
dNTP, 1 U of Hot-Start Taq DNA polymerase (Takara),1 μl
of primer mixture 1 and ~20 ng of genomic DNA. The
second PCR reaction in a 20 μl volume contained 1× GC
Buffer I (Takara), 3.0 mM Mg2+, 0.3 mM dNTP, 1 U of
Hot-Start Taq DNA polymerase (Takara),1 μl of primer
mixture 2 and ~20 ng of genomic DNA. The primer infor-





The PCR program for both reactions was 95°C 2 min;
11 cycles × (94°C 20 s, 65°C-0.5°C/cycle 40 s, 72°C 1 min
30 s); 24 cycles × (94°C 20 s, 59°C 30 s, 72°C 1 min 30 s);
and 72°C 2 min; hold at 4°C. The two PCR products were
equally mixed and purified by 1 U of shrimp alkaline
phosphatase’s digestion at 37°C for 1 hr and at 75°C for
15 min. The ligation reaction in 20 μl contains 1 × ligation
buffer, 80 U of Taq DNA Ligase (NEB), 1 μl of labeling
oligo mixture, 2 μl of probe mixture and 5 μl of purified
PCR product mixture. The oligo or probe information in













The ligation cycling program was 95°C 2 min; 38 cycles ×
(94°C 1 min, 56°C 4 min); hold at 4°C. A 0.5 μl of ligation
product was loaded in ABI 3730 × l, and the raw data were
analysed by GeneMapper 4.1. All of the primers, probes
and labeling oligos were designed by and ordered from
Genesky Biotechnologies Inc. (Shanghai, China).
Statistical analysis
Statistical analysis was performed using the SPSS pack-
age program (version 15.0 Chicago, IL, 2006). Data were
Table 1 Clinical and demographic characteristics of






Gestational age (weeks) 35.1 ± 2.0 32.2 ± 2.5 0.000
Birth weight (g) 2388 ± 625 1813 ± 504 0.000
Gender (male/female) 123/104 118/71 0.090
Apgar score (5th min) 8.1 ± 1.3 4.3 ± 1.2 0.000
Mode of delivery (V/CS) 108/119 76/113 0.132
Maternal age (years) 27.7 ± 5.4 29.0 ± 5.6 0.225
PROM >18 hours 71/156 63/126 0.655
Use of antenatal steroid 39/188 44/145 0.121
Use of surfactant 158/69 147/42 0.061
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quencies were calculated by the gene-counting method.
A statistical comparison of two groups was performed
by an unpaired Student’s t-test, while APGAR scores
were compared with the Mann–Whitney U-test. A chi-
square test was used to test the expected type frequencies,
assuming Hardy-Weinberg equilibrium. The chi-square
test or Fisher’s exact test was used for calculation of the
significance of differences in genotype and allele frequen-
cies. P < 0.05 was considered to be statistically significant.
Results
The RDS group was composed of 189 preterm infants,
and eight of the 189 infants (4.2%) died in the follow-up
period due to RDS. The control group was composed of
227 preterm infants without RDS and five (2.2%) died
for other diseases. All of the infants come from the Han
population in south China. The genotypes in the popula-
tion were in Hardy-Weinberg equilibrium (P > 0.05, dataTable 2 Genotypes and allele frequencies of the polymorphis
association with the risk of RDS





G allele 305 (67.2)





G allele 356 (78.4)
T allele 98 (21.6)not shown). The demographic characteristics of the RDS
and control groups are summarised in Table 1. Gesta-
tional age, birth weight, and the Apgar scores at the 5th
minute were found to be significantly different from the
controls (p < 0.001). There were no differences in gender,
maternal age, mode of delivery, the rates of premature
rupture of membranes (PROM), the use of antenatal
steroid and supplementary surfactant (Table 1).
As shown in Tables 2 and 3, for both NOS1-rs2682826
and NOS3-1799983 SNP loci, there were no statistically
significant differences in the genotype and allele fre-
quencies between the control and RDS groups (P > 0.05).
However, when the preterm neonates were divided into
two groups by gestational age and birth weight, the re-
sult vary. The genotype and allele frequencies were not
significantly different between the control and RDS
groups in any subgroup of GA and BW for the NOS1-
2682826 loci (p > 0.05) (Table 3).
For the NOS3-1799983 SNP loci, in the 26–32.9 weeks
of gestational age subgroup, GG and GT genotype
frequencies were 41.3% and 56.3% of the control group
and 65.8% and 30.8% of the RDS group, respectively
(P = 0.001), there were marked increases in the G allele fre-
quencies in the RDS groups in this gestational age group
(P < 0.05). In the 33–36.9 weeks of gestational age sub-
group, the difference in genotype distributions and allele
frequencies did not reach statistical significance (p > 0.05)
(Table 4). For the subgroups according to birth weight, GG
and GT genotype frequencies were 47.6% and 52.4% of the
control group and 68.8% and 23.4% of the RDS group in
the birth weight <1.5 Kg subgroup, respectively (P < 0.05),
whereas there were no significant differences in the
genotype or allele distributions between the control and
RDS groups in both the 1.5-2.5 Kg of birth weight and
birth weight >2.5 subgroups (P > 0.05) (Table 4).ms of the NOS genes in RDS and control groups and their
group (n = 189) n (%) P value OR (95% CI)
86 (45.5)
75 (39.7) 0.308 0.807 (0.534–1.200)
28 (14.8) 0.201 1.535 (0.813–2.897)
247 (65.3)
131 (34.7) 0.577 1.086 (0.814–1.449)
127 (67.2)
57 (30.2) 0.070 0.683 (0.453–1.032)
5 (2.6) 1.000 1.055 (0.298–3.731)
311 (82.3)
67 (17.7) 0.164 0.783 (0.554–1.106)
Table 3 Genotype and allele frequencies of the rs2682826 polymorphism of the NOS1 gene in RDS and the control
groups among different gestational ages and birth weights
Genotype/Allele Control group (n = 227) RDS group (n = 189) P value OR (95% CI)
Gestational age
26w≤ GA < 33 W n = 107 n = 93
GG 45 (42.1) 41 (44.1)
GT 51 (47.7) 36 (38.7) 0.405 0.775 (0.425–1.413)
TT 11 (10.3) 16 (17.2) 0.294 1.596 (0.664–3.836)
G allele 141 (65.9) 118 (63.4)
T allele 73 (34.1) 68 (36.6) 0.609 1.113 (0.738–1.679)
33w≤ GA < 37 W n = 120 n = 96
GG 54 (45.0) 45 (46.9)
GT 56 (46.7) 39 (40.6) 0.536 0.836 (0.473–1.476)
TT 10 (8.3) 12 (12.5) 0.440 1.440 (0.569–3.642)
G allele 164 (68.3) 129 (67.2)
T allele 76 (31.7) 63 (32.8) 0.800 1.054 (0.702–1.581)
Birth weight
BW < 1.5 n = 63 n = 44
GG 25 (39.7) 21 (47.7)
GT 33 (52.4) 19 (43.2) 0.360 0.685 (0.305–1.540)
TT 5 (7.9) 4 (9.1) 1.000 0.952 (0.226–4.008)
G allele 83 (65.9) 61 (69.3)
T allele 43 (34.1) 27 (30.7) 0.597 0.854 (0.477–1.532)
1.5 < BW < 2.5 n = 86 n = 70
GG 36 (41.9) 31 (44.3)
GT 42 (48.8) 32 (45.7) 0.718 0.885 (0.455–1.720)
TT 8 (9.3) 7 (10.0) 0.978 1.106 (0.331–3.122)
G allele 114 (66.3) 94 (67.1)
T allele 58 (33.7) 46 (32.9) 0.872 0.962 (0.599–1.545)
BW > 2.5 n = 85 n = 75
GG 38 (44.7) 34 (45.3)
GT 32 (37.6) 24 (32.0) 0.623 0.838 (0.415–1.693)
TT 15 (17.6) 17 (22.7) 0.578 1.267 (0.550–2.918)
G allele 108 (63.5) 92 (61.3)
T allele 62 (36.5) 58 (38.7) 0.686 1.098 (0.698–1.728)
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ness in the groups of RDS infants with the rs1799983
(GG) and rs1799983 combined genotype (GT + TT), and
we observed that the frequencies of the rs1799983 poly-
morphism did not markedly influence the complications,
duration of oxygen therapy, mechanical ventilation (in-
cluding CPAP) and hospitalisation. There were also no
statistically significant differences between the demo-
graphic characteristics of the two groups except for ges-
tational age, birth weight and use of antenatal steroid
between the genotypes (Table 5).Discussion
RDS is a multifactorial disease, and several genetic fac-
tors could interact with environmental factors in deter-
mining the risk of the disease. Both the incidence and
severity of RDS have decreased markedly since the
introduction of antenatal steroids and pulmonary sur-
factant replacement therapy, yet the incidence of com-
plications remains a cause of concern [10]. Several
mutations and polymorphisms within various genes,
especially surfactant-associated genes, have previously
been suggested to be modifiers of the risk for and
Table 4 Genotype and allele frequencies of the rs1799983 polymorphism of the NOS3 gene in RDS and the control
groups among different gestational ages and birth weights
Genotype/Allele Control group (n = 227) RDS group (n = 189) P value OR (95% CI)
Gestational age
26w≤ GA < 33 W n = 80 n = 117
GG 33 (41.3) 77 (65.8)
GT 45 (56.3) 36 (30.8) 0.001 0.343 (0.188-0.624)
TT 2 (2.4) 4 (3.4) 1.000 0.857 (0.150-4.911)
G allele 111 (69.4) 190 (81.2)
T allele 49 (30.6) 44 (18.8) 0.007 0.525 (0.328-0.839)
33w≤ GA < 37 W n = 147 n = 72
GG 101 (68.7) 50 (69.4)
GT 43 (29.3) 21 (29.2) 1.000 0.987 (0.530-1.838)
TT 3 (2.0) 1 (1.4) 1.000 0.673 (0.068-6.639)
G allele 245 (83.3) 121 (84.0)
T allele 49 (16.7) 23 (16.0) 0.892 0.950 (0.553-1.633)
Birth weight
BW < 1.5 n = 21 n = 64
GG 10 (47.6) 44 (68.8)
GT 11 (52.4) 15 (23.4) 0.031 0.310 (0.110-0.875)
TT 0 (0) 5 (7.8) - -
G allele 31 (73.8) 103 (80.5)
T allele 11 (26.2) 25 (19.5) 0.387 0.684 (0.303-1.545)
1.5 < BW < 2.5 n = 105 n = 106
GG 73 (69.5) 71 (67.0)
GT 30 (28.6) 35 (33.0) 0.554 1.200 (0.667-2.157)
TT 2 (1.9) 0 (0) - -
G allele 176 (83.8) 177 (83.5)
T allele 34 (16.2) 35 (16.5) 1.000 1.024 (0.611-1.715)
BW > 2.5 n = 101 n = 19
GG 51 (50.5) 12 (63.2)
GT 47 (46.5) 7 (36.8) 0.455 0.633 (0.230-1.743)
TT 3 (3.0) 0 (0) - -
G allele 149 (73.8) 31 (81.6)
T allele 53 (26.2) 7 (18.4) 0.414 0.635 (0.264-1.527)
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tigators have reported a higher risk for RDS in neo-
nates who carry the surfactant protein A1(SP-A1) 6A2
allele [11], surfactant protein B(SP-B) 131Thr allele
[12], or surfactant protein C(SP-C) 138Asn allele [13].
There is also an association between a synonymous
code SNP rs323043 of the ATP-binding cassette trans-
porter A3 gene (ABCA3) and the development of RDS
[14]. On the other hand, the presence of inflammatory
genes, including the MaNOS1e-binding lectin gene
(MBL2), tumour necrosis factor (TNF) and the interferon
gamma gene (IFNG), did not alter the risk of RDS [15].Moreover, the 6A3 allele of surfactant protein A1(SP-A1)
was less common among preterm infants with RDS and
was absent among those with severe RDS, which sug-
gests a possible protective role for this allele or other
genes with which it is in linkage disequilibrium in RDS
[11]. Glutathione-S-transferase-P1 (GSTP1) I105V poly-
morphism and Angiotensin converting enzyme (ACE)
gene deletion/deletion polymorphism have also been
reported to be protective factors for respiratory dis-
tress in preterm infants, and another study showed
that angiotensin-converting enzyme gene polymor-
phism did not impact the risk or severity of persistent
Table 5 Effect of rs1799983 polymorphism of NOS3 gene
on characteristics and severity of illness among RDS
infants
GG genotype
(n = 129 )
GT + TT genotype
(n = 60 )
P value
Gestational age (weeks) 33.0 ± 2.5 31.3 ± 2.1 0.000
Birth weight (g) 2050 ± 575 1753 ± 373 0.000
Gender (male/female) 79/50 39/21 0.619
Mode of delivery (V/CS) 47/82 29/31 0.120
PROM > 18 h 41/88 22/38 0.507
Use of antenatal steroid 24/105 20/40 0.026
Use of surfactant 98/31 49/11 0.380
Days of oxygen 38.3 ± 23.4 39.8 ± 25.7 0.135
Days of ventilation 20.1 ± 13.4 19.7 ± 15.6 0.407
Days of hospitalization 43.8 ± 21.6 42.2 ± 17.3 0.075
Complications
PDA 27/102 18/42 0.173
BPD 32/97 11/49 0.323
ROP 11/118 9/51 0.178
IVH 14/115 2/58 0.098
V: Vaginal delivery; CS: cesarean section; PROM: premature rupture of
membranes; PDA: patent ductus arteriosus; BPD: bronchopulmonary dysplasia;
ROP: retinopathy of prematurity; IVH: intraventricular hemorrhage.
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fants >34 weeks GA [16-18]. Many of these associations
with RDS have not been tested in multiple independent
populations or have not been consistently replicated
across studies.
Nitric oxide mediates multiple physiological func-
tions, including neurotransmission, immunoregulation,
angiogenesis, antiplatelet activity, and surfactant mat-
uration or secretion. Given the many physiological
roles for NO and its rapid reaction and inactivation in
cellular systems, strict control of NO production is
crucial for its selective actions. NO is critical for the
maturation of pulmonary structure and function. Re-
search in animals has suggested that NOS3 gene-
deficient mice suffered defective lung vascular devel-
opment and fatal respiratory distress [2].
Several polymorphic variations of the NOS3 gene are
now known and have been investigated with respect to
disease risk. A few literature reports have revealed that the
NOS3 gene Glu298Asp (rs1799983) polymorphism is as-
sociated with an increased incidence of cardiovascular dis-
orders and cerebrovascular diseases [19]. Godfrey V et al.’s
study of the functional consequence of the Glu298Asp
polymorphism in young healthy volunteers showed that
this loci was associated with a blunted endothelial-
dependent vasodilation, which possibly results from
decreased NO synthesis [20]. Savvidou et al. showed
that the Glu298Asp polymorphism was associated withdifferences in endothelium-dependent dilation at a 12-
week gestation, thus implicating genetic factors in the
normal vascular adaptation to pregnancy [21].
This study is the first to examine the impact of the
NOS1 gene polymorphism on the risk and severity of
RDS in preterm infants; we found no significant differ-
ence in the genotype or allele frequencies between the
control and the RDS infants. Similarly, the difference
in the genotype distributions of the NOS3 gene be-
tween the two groups did not reach statistical sig-
nificance. However, when the preterm infants were
divided into two groups by gestational age and three
groups by birth weight, we found that, for the NOS3
gene, the GG genotype and G allele increased while the
GT genotype and T allele decreased, and infants with
the GG genotype and G allele of NOS3 were less likely
to have development of RDS in the 26–32.9 weeks of
gestational age subgroup and the birth weight <1.5 Kg
subgroup.
Two meta-analyses showed that inhaled nitric oxide
could alleviate persistent pulmonary hypertension in the
neonates, but for the treatment of respiratory failure in
preterm infants, routine use of inhaled nitric oxide can-
not be recommended [22,23]. It is reported that com-
mon variants in the NO synthesis pathway genes jointly
contribute to differences in exhaled nitric oxide (FeNO)
levels in children, which is a biomarker of airway inflam-
mation, most likely through differential gene expression
[24-26]. In Gravesande et al.’ s study, the T allele is asso-
ciated with lower NO levels, which demonstrates that
the Glu298Asp polymorphism is functionally relevant
and could be a reason for the low FeNO levels [27]. In
placental tissue, Wang and coworkers showed that the
Glu298Asp variant influences NOS3 expression and en-
zyme activity [28]. One possible mechanism by which
the GG genotype and G allele of NOS3 could influence
the risk of RDS in very preterm and very low birth
weight infants in the present study could be through the
generation of low levels of FeNO, which could mitigate
lung inflammation and interfere with pulmonary vascu-
lar remodelling, thus determination of FeNO or plasma
levels of NO metabolites is worthy for further study.
This polymorphism leads to the alteration of NOS3 en-
zyme activity and is associated with the reduced basal
NO product.
A limitation of our study is that our sample size was
not large enough to compare the control and RDS
groups, which could lead to false-negative results in as-
sociation studies. The sample was not large enough to
explore gene by gene interactions, it is possible that
having more than one susceptibility gene could result
in different respiratory outcomes. Furthermore, only
two polymorphisms that are potentially involved in
RDS pathogenesis have been considered in this paper;
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different genes cannot be excluded.
In conclusion, our data suggest the lack of an associa-
tion between the rs2682826 polymorphism of the NOS1
gene and the development of RDS in a Chinese Han popu-
lation. We observed that there is a gestational age and
birth weight -related association between the rs1799983
polymorphism of the NOS3 gene and the development of
RDS in this population. However, further investigations of
NOS3 genetic variations in combination with other rele-
vant genes (especially those involved in pulmonary sur-
factant and Lipid metabolism) will most likely provide
more mechanistic insight into RDS processes. Additional
identification of how NOS3 genetic variation is translated
to altered enzyme and/or cellular function will also be in-
formative. This pilot study could offer data on which fur-
ther studies can be planned. Very large-scale studies of
genetic, environmental and obstetric factors will be needed
before effective preventative strategies can be devised.
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